53BP1 loss suppresses the radiosensitizing effect of icotinib hydrochloride in colorectal cancer cells

References

• Ausborn NL, Wang T, Wentz SC, Washington MK, Merchant NB, Zhao Z, Shyr Y, Chakravarthy AB, Xia F. 2013. 53BP1 expression is a modifier of the prognostic value of lymph node ratio and CA 19-9 in pancreatic adenocarcinoma. BMC Cancer. 13:155.
   PubMed Web of Science ®Google Scholar
• Bi J, Huang A, Liu T, Zhang T, Ma H. 2015. Expression of DNA damage checkpoint 53BP1 is correlated with prognosis, cell proliferation and apoptosis in colorectal cancer. Int J Clin Exp Pathol. 8:6070–6082.
   PubMed Web of Science ®Google Scholar
• Bohgaki M, Bohgaki T, El Ghamrasni S, Srikumar T, Maire G, Panier S, Fradet-Turcotte A, Stewart GS, Raught B, Hakem A, et al. 2013. RNF168 ubiquitylates 53BP1 and controls its response to DNA double-strand breaks. Proc Natl Acad Sci USA. 110:20982–20987.
   PubMed Web of Science ®Google Scholar
• Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC, et al. 2006. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 355:1114–1123.
   PubMed Web of Science ®Google Scholar
• Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, et al. 2010. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol. 17:688–695.
   PubMed Web of Science ®Google Scholar
• Carr SM, Munro S, Zalmas LP, Fedorov O, Johansson C, Krojer T, Sagum CA, Bedford MT, Oppermann U, La Thangue NB. 2014. Lysine methylation-dependent binding of 53BP1 to the pRb tumor suppressor. Proc Natl Acad Sci USA. 111:11341–11346.
   PubMed Web of Science ®Google Scholar
• Haffty BG, Goyal S, Kulkarni D, Green C, Vazquez A, Schiff D, Moran MS, Yang Q, Ganesan S, Hirsfield KM. 2011. Evaluation of single nucleotide polymorphisms (SNPs) in the p53 binding protein 1 (TP53BP1) gene in breast cancer patients treated with breast-conserving surgery and whole-breast irradiation (BCS + RT). Int J Radiat Oncol Biol Phys. 80:385–391.
   PubMed Web of Science ®Google Scholar
• Haggblad Sahlberg S, Spiegelberg D, Lennartsson J, Nygren P, Glimelius B, Stenerlow B. 2012. The effect of a dimeric Affibody molecule (ZEGFR:1907)2 targeting EGFR in combination with radiation in colon cancer cell lines. Int J Oncol. 40:176–184.
   PubMed Web of Science ®Google Scholar
• Harari PM, Huang SM. 2001. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys. 49:427–433.
   PubMed Web of Science ®Google Scholar
• Knappskog S, Chrisanthar R, Lokkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, et al. 2012. Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res. 14:R47.
   PubMed Web of Science ®Google Scholar
• Ma H, Bi J, Liu T, Ke Y, Zhang S, Zhang T. 2015. Icotinib hydrochloride enhances the effect of radiotherapy by affecting DNA repair in colorectal cancer cells. Oncol Rep. 33:1161–1170.
   PubMed Web of Science ®Google Scholar
• Mardjuadi FI, Carrasco J, Coche JC, Sempoux C, Jouret-Mourin A, Scalliet P, Goeminne JC, Daisne JF, Delaunoit T, Vuylsteke P, et al. 2015. Panitumumab as a radiosensitizing agent in KRAS wild-type locally advanced rectal cancer. Targ Oncol. 10:375–383.
   PubMed Web of Science ®Google Scholar
• Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z. 2000. enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 6:701–708.
   PubMed Web of Science ®Google Scholar
• Morales JC, Franco S, Murphy MM, Bassing CH, Mills KD, Adams MM, Walsh NC, Manis JP, Rassidakis GZ, Alt FW, et al. 2006. 53BP1 and p53 synergize to suppress genomic instability and lymphomagenesis. Proc Natl Acad Sci USA. 103:3310–3315.
   PubMed Web of Science ®Google Scholar
• Neboori HJ, Haffty BG, Wu H, Yang Q, Aly A, Goyal S, Schiff D, Moran MS, Golhar R, Chen C, et al. 2012. Low p53 binding protein 1 (53BP1) expression is associated with increased local recurrence in breast cancer patients treated with breast-conserving surgery and radiotherapy. Int J Radiat Oncol Biol Phys. 83:e677–e683.
   PubMed Web of Science ®Google Scholar
• Panier S, Durocher D. 2013. Push back to respond better: regulatory inhibition of the DNA double-strand break response. Nat Rev Mol Cell Biol. 14:661–672.
   PubMed Web of Science ®Google Scholar
• Rodel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, Graeven U, Arnold D, Lang-Welzenbach M, Raab HR, et al. 2012. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 13:679–687.
   PubMed Web of Science ®Google Scholar
• Rybanska-Spaeder I, Reynolds TL, Chou J, Prakash M, Jefferson T, Huso DL, Desiderio S, Franco S. 2013. 53BP1 is limiting for NHEJ repair in ATM-deficient model systems that are subjected to oncogenic stress or radiation. Mol Cancer Res. 11:1223–1234.
   PubMed Web of Science ®Google Scholar
• Shin SJ, Yoon HI, Kim NK, Lee KY, Min BS, Ahn JB, Keum KC, Koom WS. 2011. Upfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases. Radiat Oncol. 6:99.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Munshi A, Brooks C, Liu J, Hobbs ML, Meyn RE. 2008. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res. 14:1266–1273.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Zheng X, Huang A, Liu T, Zhang T, Ma H. 2016. Deficiency of 53BP1 inhibits the radiosensitivity of colorectal cancer. Int J Oncol. 49:1600–1608.
   PubMed Web of Science ®Google Scholar
• Yao J, Huang A, Zheng X, Liu T, Lin Z, Zhang S, Yang Q, Zhang T, Ma H. 2017. 53BP1 loss induces chemoresistance of colorectal cancer cells to 5-fluorouracil by inhibiting the ATM-CHK2-P53 pathway. J Cancer Res Clin Oncol. 143:419–431.
   PubMed Web of Science ®Google Scholar